peoplePerson
David B. Solit
Built MSK-IMPACT, the first FDA-authorised tumour sequencing panel, and the clinical genomics programme behind OncoKB and cBioPortal.
Directs the Kravis Center for Molecular Oncology, which developed MSK-IMPACT and sequenced tens of thousands of tumours, defining the landscape of actionable alterations and genomic determinants of exceptional responses.
Role
Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Institution
Specialisms
Cancer genomicsMSK-IMPACTExceptional respondersBladder cancer
| Title | Journal | Year |
|---|---|---|
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients | Nature Medicine | 2017 |
Pages like this
not linked directly; found by shared links- TechnologyCancer variant knowledgebases and molecular tumour boards
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.
- InstitutionOslo University Hospital – The Norwegian Radium Hospital
Shares Comprehensive genomic profiling, Bladder & urothelial cancer.
- TargetPRMT5 (MTAP-deleted cancers)
Shares Comprehensive genomic profiling, Bladder & urothelial cancer.
- CollectionOncoKB
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.
- CollectioncBioPortal for Cancer Genomics
Shares Memorial Sloan Kettering Cancer Center, Comprehensive genomic profiling.